Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNF | P01375 | 1/20 | 0.68 |
| ▸ | ITGB2 | P05107 | 9/20 | 0.56 |
| ▸ | ICAM1 | P05362 | 9/20 | 0.56 |
| ▸ | ITGAL | P20701 | 9/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | ACE | P12821 | 3/20 | 0.49 |
| ▸ | TACR1 | P25103 | 1/20 | 0.47 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL837864 | 1.00 | TNF (0.68) | TNFITGB2ICAM1ITGALALOX15 | |
| SCHEMBL837759 | 0.88 | ITGB2 (0.53) | TNFITGB2ICAM1ITGALALOX15 | |
| SCHEMBL28516957 | 0.86 | ITGB2 (0.63) | TNFITGB2ICAM1ITGALALOX15 | |
| SCHEMBL28516953 | 0.86 | ITGB2 (0.63) | TNFITGB2ICAM1ITGALALOX15 | |
| SCHEMBL29530632 | 0.85 | TNF (0.71) | TNFITGB2ICAM1ITGALALOX15 | |
| SCHEMBL4002154 | 0.85 | TNF (0.61) | TNFITGB2ICAM1ITGALALOX15 | |
| SCHEMBL32684016 | 0.85 | ITGB2 (0.50) | TNFITGB2ICAM1ITGALALOX15 | |
| SCHEMBL31407308 | 0.84 | ACE (0.56) | TNFITGB2ICAM1ITGALACE | |
| SCHEMBL859945 | 0.83 | TNF (0.47) | TNFITGB2ICAM1ITGALTACR1 | |
| SCHEMBL10182650 | 0.82 | CTSL (0.48) | TNFITGB2ICAM1ITGALALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3081214-A2 | INHIBITORS OF CELLULAR NECROSIS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2016-10-19 | — | — | EP | disclosed |
| EP-3081214-A2 | INHIBITORS OF CELLULAR NECROSIS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2016-10-19 | — | — | EP | disclosed |
| EP-2384753-B1 | Hydantoin derivatives as inhibitors of cellular necrosis | BRIGHAM & WOMENS HOSPITAL (US) | 2016-01-06 | — | — | EP | disclosed |
| EP-2384753-B1 | Hydantoin derivatives as inhibitors of cellular necrosis | BRIGHAM & WOMENS HOSPITAL (US) | 2016-01-06 | — | — | EP | disclosed |
| US-8741942-B2 | Inhibitors of cellular necrosis | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2014-06-03 | — | — | US | disclosed |
| US-8741942-B2 | Inhibitors of cellular necrosis | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2014-06-03 | — | — | US | disclosed |
| US-8741942-B2 | Inhibitors of cellular necrosis | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2014-06-03 | — | — | US | disclosed |
| US-20120149702-A1 | INHIBITORS OF CELLULAR NECROSIS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2012-06-14 | — | — | US | disclosed |
| US-20120149702-A1 | INHIBITORS OF CELLULAR NECROSIS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2012-06-14 | — | — | US | disclosed |
| US-20120149702-A1 | INHIBITORS OF CELLULAR NECROSIS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2012-06-14 | — | — | US | disclosed |
| EP-2384753-A1 | Hydantoin derivatives as inhibitors of cellular necrosis | The Brigham and Women's Hospital, Inc. (US) | 2011-11-09 | — | — | EP | disclosed |
| US-20110144169-A1 | Inhibitors of cellular necrosis | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-06-16 | — | — | US | disclosed |
| US-20110144169-A1 | Inhibitors of cellular necrosis | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-06-16 | — | — | US | disclosed |
| US-20110144169-A1 | Inhibitors of cellular necrosis | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-06-16 | — | — | US | disclosed |
| US-7491743-B2 | Inhibitors of cellular necrosis | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2009-02-17 | — | — | US | disclosed |
| US-7491743-B2 | Inhibitors of cellular necrosis | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2009-02-17 | — | — | US | disclosed |
| US-7491743-B2 | Inhibitors of cellular necrosis | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2009-02-17 | — | — | US | disclosed |
| EP-1663184-A2 | HYDANTOIN DERIVATIVES AS INHIBITORS OF CELLULAR NECROSIS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2006-06-07 | — | — | EP | disclosed |
| WO-2005077344-A2 | HYDANTOIN DERIVATIVES AS INHIBITORS OF CELLULAR NECROSIS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2005-08-25 | — | — | WO | disclosed |
| US-20050119260-A1 | Inhibitors of cellular necrosis | BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2005-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050119260-A1 | Inhibitors of cellular necrosis | TNF, AIFM1, BAD | TNF 1/4885ITGB2 3467/4885ICAM1 478/4885 |
| US-20110144169-A1 | Inhibitors of cellular necrosis | TNF, AIFM1, BAD | TNF 1/4885ITGB2 3467/4885ICAM1 478/4885 |
| US-20120149702-A1 | INHIBITORS OF CELLULAR NECROSIS | TNF, AIFM1, BAD | TNF 1/4885ITGB2 3467/4885ICAM1 478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.